Trametinib as MEK inhibitor and Dabrafenib as serine-threonine kinase (BRAF) inhibitor are the chemotherapeutics that can be used in non-small cell lung carcinoma (NSCLC). This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.